Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed vs flexible insulin aspart regimen (with/without insulin detemir) in type 2 diabetes over 52 weeks
2005-000319-87Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: HbA1c at 52 weeks. Started Jun 2005; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-000319-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000319-87.